Clinical efficacy of plasmid encoding p62/SQSTM1 (Elenagen) in combination with gemcitabine in patients with platinum-resistant ovarian cancer: a randomized controlled trial.
Journal Information
Full Title: Front Oncol
Abbreviation: Front Oncol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Conflict of interest VG and AS are employees of CureLab Oncology, which holds the intellectual property (IP) to the Elenagen treatment. The clinical trial registration was retrospective. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."
"The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was funded by Ministry of Health of Belarus and CureLab Oncology."
"Clinical trial registration https://www.clinicaltrials.gov/study/NCT05979298, identifier NCT05979298, 2023-08-07."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025